The U.S. Supreme Court has ruled that Amarin failed to plausibly allege that Hikma Pharmaceuticals actively encouraged infringement of its cardiovascular-use patents, reversing a Federal Circuit decision that allowed the patent inducement claim to move forward.
The case centred on Vascepa, Amarin’s prescription drug containing icosapent ethyl, and patents covering certain cardiovascular uses of the medicine. Amarin alleged that statements appearing across Hikma’s product label, patient information leaflet, website and investor communications encouraged healthcare providers to prescribe Hikma’s generic version for those patented uses.
The Court ultimately concluded that the complaint failed to plausibly allege the kind of affirmative conduct required to establish inducement liability under 35 U.S.C. §271(b), reversing a Federal Circuit decision that had allowed the lawsuit to proceed.
Amarin’s claim rested on a collection of statements appearing across Hikma’s product label, patient information leaflet, website and investor communications. According to the complaint, those materials encouraged healthcare providers to prescribe Hikma’s generic product for cardiovascular-risk reduction, a use covered by Amarin’s patents.
The Court disagreed, holding that inducement requires affirmative conduct directed toward infringement rather than a chain of inferences built on how third parties might understand lawful communications. Hikma’s statements, viewed individually or collectively, did not plausibly cross that line.
Legal Issue Overview
Hikma Pharmaceuticals obtained FDA approval to market a generic version of Vascepa, a prescription drug containing icosapent ethyl.
Patents covering the drug’s cardiovascular-risk indication remained in force, but Hikma pursued approval using a “skinny label” that carved out the patented use while retaining approval for the treatment of severe hypertriglyceridemia.
The lawsuit alleged that statements appearing across Hikma’s label, patient information leaflet, website and press releases encouraged healthcare providers to prescribe the generic product for patented cardiovascular uses. The Supreme Court rejected that argument, holding that the complaint failed to plausibly allege the affirmative conduct required for inducement liability under 35 U.S.C. §271(b).
Risk Emergence
Legal risk first emerges when a company’s communications move beyond describing an approved product and begin encouraging conduct covered by another party’s patent rights. The Court’s ruling confirms that exposure does not arise merely because infringement is foreseeable. Exposure begins when affirmative conduct can reasonably be interpreted as promoting the patented activity itself.
Applicable Legal Framework and Compliance Obligations
The Supreme Court’s analysis focused on whether Hikma’s conduct went beyond lawful commercial activity and crossed into active encouragement of patent infringement.
An inducement claim under 35 U.S.C. §271(b) requires direct infringement by a third party, knowledge that the conduct constitutes infringement, and active steps taken to encourage that infringement. The dispute in Hikma v. Amarin concerned only the third requirement. The Court found that the complaint failed to plausibly allege the affirmative conduct needed to satisfy that element.
Hikma’s label, website materials and public statements were alleged to encourage patented uses of the drug, but the Court concluded that the possibility of doctors or pharmacists interpreting otherwise lawful communications in a particular way was not enough to establish inducement.
Several of the statements challenged by Amarin had alternative explanations rooted in regulatory requirements or ordinary industry practice. Generic manufacturers are generally required to maintain labeling that mirrors the branded product except where patented uses have been carved out, and describing a product as the generic equivalent of a branded medicine is a routine feature of the pharmaceutical market.
The ruling leaves intact the risk of inducement claims where communications are used to promote patented uses, but it draws a clearer line around conduct tied to regulatory compliance. Companies relying on skinny-label approvals will still need to review labeling, marketing materials, investor communications and launch-related messaging where patented and non-patented uses exist side by side. Materials created outside the FDA approval process are more difficult to defend if they appear to encourage uses protected by an existing patent.
Exposure Escalation
Exposure escalates when communications can no longer be justified as regulatory compliance, scientific disclosure or ordinary industry practice. Once messaging appears intended to influence prescribing behaviour toward patented uses, organisations move from a defensible compliance position into an area where litigation risk may become materially more difficult to manage.
Liability and Risk Analysis
One of the most important aspects of the ruling concerns omissions and indirect inferences. Amarin argued that Hikma’s failure to include certain information in its communications contributed to inducement, but the Supreme Court rejected that argument, explaining that inducement liability requires affirmative statements or actions rather than mere omissions, inaction or nonfeasance.
The Court was equally sceptical of arguments built on extended chains of inference, finding that the possibility of doctors, pharmacists or other healthcare providers interpreting lawful communications in a particular way was not enough to establish inducement.
Decision Trigger
The decision trigger occurs when commercial communications can no longer be defended as ordinary compliance activity and instead appear directed toward influencing patented uses. Once that threshold is crossed, the issue moves beyond routine legal monitoring and becomes a governance matter capable of creating material litigation exposure.
Regulatory and Practical Implications
The decision preserves the viability of the skinny-label pathway under the Hatch-Waxman framework. The Supreme Court repeatedly pointed to the regulatory obligations imposed on generic manufacturers, including the requirement that labels generally mirror branded products except where patented uses have been carved out.
The complaint relied heavily on how doctors, pharmacists and patients might interpret Hikma’s communications. The Court found that approach insufficient, concluding that inducement liability requires affirmative conduct rather than speculation about how third parties may understand otherwise lawful statements.
Several of the statements challenged by Amarin had alternative explanations rooted in regulatory requirements and ordinary industry practice. Generic-equivalent descriptions, mirrored labeling and other compliance-driven communications formed part of the Court’s analysis.
Broader Legal Pattern
The broader signal from the Court is that inducement claims depend on identifiable affirmative conduct rather than speculation about how third parties may interpret lawful communications. The opinion repeatedly distinguishes active encouragement from regulatory compliance, ordinary commercial activity and omissions, reinforcing the requirement that liability be tied to purposeful conduct directed toward infringement.
The Court’s Holding
The Supreme Court reversed the Federal Circuit and remanded the case for further proceedings, concluding that Amarin failed to plausibly allege active inducement under 35 U.S.C. §271(b).
The decision leaves intact inducement claims based on affirmative conduct encouraging infringement, while rejecting theories built on omissions, routine compliance activities and speculation about how third parties may interpret lawful communications. It also preserves the use of FDA-approved skinny labels where patented and non-patented uses of a drug exist side by side.